Re: Information for Shareholders
in response to
by
posted on
May 07, 2015 08:10AM
Paramagnetic Beads and QL Analyser are Proprietary Products
The prevalence of hypertension was found to increase with age, occurring more frequently in Arab women3
Caution leading doctors at the Mind to Heart Cardio-Vascular scientific exchange forum, introducing the latest advancements in Cardio Vascular Diseases (CVD) and their role in disease prevention
Istanbul, Turkey, May 30, 2014: – As the percentage of the Middle East population over 60 rapidly expands over the next few decades, atrial fibrillation and hypertension are the key cardiovascular problems expected to become much more prevalent in the region. Atrial fibrillation (AF) is the most common cause of hospital admission in the Gulf region of the Middle East1. Stroke is increasingly becoming a major health problem, with projections that deaths from it will nearly double by 2030. Studies reported prevalence rates from 29.8 per cent in Saudi Arabia to 57 per cent Bahrain.
Cardiovascular Diseases (CVD) have emerged as the leading cause of death in most countries in the Middle East over the past few decades. This is the primary objective of Boehringer Ingelheim’s conference “Mind to Heart Cardio-Vascular Scientific Exchange” which brought together 170 international and regionally renowned senior healthcare care practitionersto identify and bridge gaps that would help reap the biggest reductions of the CVD burden.
On the other hand, the consequences of hypertension for MENA are sobering. If untreated, hypertension leads to ischemic heart disease and stroke, the leading causes of death and disability in MENA. The economic costs of hypertension are also sizable as mentioned below-
UAE | 37.3 | Egypt | 26.3 |
KSA | 26.1 | Lebanon | 23 |
Jordan | 16.3 |
At the conference, Boeringher Ingelheim introduced some of the latest finding from its recently concluded study, called RE-SPECT ESUS,™ on prevention of recurrent stroke in high-risk patients.4 Conducted amongst 6000 patients, the study aimed to aid doctors in controlling the factors that lead to recurrence of stroke amongst high patients. This is in addition to increased investment by the company in introducing innovative treatment in the field of stroke prevention and cardiology.5
In the Middle East, atrial fibrillation is more common in women than in men. Considering regional increases in sedentary lifestyles, ageing, obesity, diabetes, hypertension, and coronary heart disease—all predisposing factors is adding to the vicious circle of hypertension, atrial fibrillation and stroke in the Middle East.6
Dr. Mohammad AI Kurdi, Interventional Cardiology consultant and Head of Cardiac Centre, said, “According to different surveys and registries, hypertension and atrial fibrillations are considered as a common risk factors affecting population in the Middle East region, which lead to serious complications such as renal disorders, heart disease and stroke. The findings from a recent report on the prevalence of hypertension and atrial fibrillation indicate a higher prevalence of these diseases in Arab countries compared to the USA and sub-Saharan Africa.”
Dr. Yasser El Shahawy, Regional Medical Affairs Manager, Cardiovascular, Responsible for Middle East and North Africa region, Iran and Pakistan at Boehringer Ingelheim, commented, "Despite focused efforts and the introduction of multiple new therapies, the percentage of hypertension patients resistant to treatment has increased by 62 percent in the last 20 years – making it critical for physicians across all disciplines, to work together with patients, to improve disease management. This conference is one of many efforts undertaken by us to bridge knowledge gaps and support governments as well as health care professionals in prioritizing, responding and managing the rising tide of cardiovascular diseases.”
The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies.Headquartered in Ingelheim, Germany, Boehringer Ingelheim operates globally with 142 affiliates and a total of more than 47,400 employees. The focus of the family-owned company, founded in 1885, is researching, developing, manufacturing and marketing new medications of high therapeutic value for human and veterinary medicine.
Taking social responsibility is an important element of the corporate culture at Boehringer Ingelheim. This includes worldwide involvement in social projects, such as the initiative “Making more Health” and caring for the employees. Respect, equal opportunities and reconciling career and family form the foundation of the mutual cooperation. In everything it does, the company focuses on environmental protection and sustainability.
In 2013, Boehringer Ingelheim achieved net sales of about 14.1 billion euros. R&D expenditure corresponds to 19.5% of its net sales.
For more information please visit www.boehringer-ingelheim.com
Corporate Communications
Media + PR
Head of Communications
Omneya Fawzy